Related by context. All words. (Click for frequent words.) 63 Content Outline 61 Cardiotoxicity 61 Clinical Outcome 60 Outpatient Setting 60 Dose Ranging 60 Oral Fingolimod 60 See CLINICAL PHARMACOLOGY 60 PRE SURGE 60 prospective multicentre 60 Test Methodology 60 Prostate AdenoCarcinoma Treatment 60 Gastrointestinal Stromal Tumors 60 TRANSFORMS 60 By JENNIFER LEARN 59 MoxDuo TM IR 59 Structured Content 59 TMC# C# 59 Syllego system 59 Natalizumab 59 Pulmonary Arterial Hypertension 59 Natural Catastrophe Stress 59 Trandolapril 59 SAP BusinessObjects Edge 59 Prospective Multicenter 59 Gynecol Oncol 58 PREDICTIVE 58 Immunotherapeutic 58 Outsourcing Providers 58 UNLOAD 58 BCIRG 58 Data Extraction 58 Watson LIMS 58 NO# [002] 58 Veracity ™ 58 First Patient Enrolled 58 ANCHOR trial 58 Pharmacokinetic PK 58 JETNET iQ 58 ALN TTR 58 FOR AN OPEN 58 Clinical Trial Data 58 Phase IIIb 58 Protein Expression 58 Prospective Randomized 58 Tumor Response 58 Randomized Double blind 58 Phase Ib Clinical Trial 58 Left Ventricular Dysfunction 58 Continuous Monitoring 58 Randomized Double Blind Placebo 57 ONTARGET 57 Vertebral Fracture 57 Demonstrates Significant 57 Phase Ib II 57 Initiated Phase 57 STRIDE PD 57 eReview 57 SMARTREND NEWS 57 Hsp# Inhibitor 57 Reproducibility 57 ENESTnd 57 Phase Forward InForm 57 aspenONE V7 57 Lp PLA 2 57 Arbortext IsoDraw 57 Adverse Event 57 Therapeutic Arthritis 57 Quality Indicators 57 oral FTY# 57 vitro ADME 57 STRATEGY FOR AN OPEN 57 HCV SPRINT 57 NABTT 57 CRMD# 57 Schizophrenia Treatment 57 InfoCommerce 57 Nord Trøndelag Health 57 Myocardial Perfusion Imaging 57 Patient Recruitment 57 Multicenter 57 ISPOR 57 Outcome Measures 57 TRANSDUR ™ 57 Oligonucleotides 57 Study Evaluating 57 CURRENT OASIS 7 57 Datamaker 57 Metabolic Endocrinology 57 Deforolimus 57 REMINYL ® 57 Prolongs Survival 57 Quantifiable 57 Multicenter Phase 57 Improve Processes 57 HCV Protease Inhibitor 57 PRoFESS 57 multicenter Phase II 57 Sorafenib HCC Assessment 57 PSMA ADC 57 ASTEROID 57 CRLX# 57 PROactive Study 57 Vertebral Fractures 57 AVADO 57 RECORD1 57 SUCCEED trial 56 Attensity Cloud 56 Randomized Evaluation 56 Randomized Phase III 56 Anti CD# Antibody 56 Topline Results 56 Pivotal Phase 56 Patient Adherence 56 Biopharmaceutical Industry 56 Combination REOLYSIN R 56 LUX Lung 56 PROactive 56 OLYMPIA registry 56 Phase III Clinical Trial 56 Aromatase Inhibitors 56 clinical pharmacology studies 56 Demonstrates Sustained 56 Arch Neurol 56 Diamyd Medical Diamyd 56 Roadmapping 56 IDS Scheer ARIS 56 Critical Success Factors 56 ILOG JRules ILOG Rules 56 Truvada tablets 56 number NCT# ClinicalTrials.gov 56 Solution Integrates 56 Laryngeal Cancer 56 CYT# potent vascular disrupting 56 RE LY ® 56 enzyme immunoassay EIA 56 Confirmatory Phase 56 Platelet Function 56 Heart Failure Therapies 56 EGFR HER2 56 Immunostimulatory 56 Mercury BTO 56 Phase 2a Trial 56 Cholinesterase Inhibitors 56 Novel Oral 56 Nucleic Acids 56 Telelogic DOORS 56 Bionanotechnology 56 BRIM3 56 Innate Immune 56 www.givenimaging.com 56 LUMINATE 56 Acute Ischemic Stroke 56 Shows Efficacy 56 Adaptive Clinical Trials 56 IIa clinical 56 CombAT 56 Cardiac Allograft Rejection 56 Hormone Refractory Prostate Cancer 56 riskpro ™ 56 Sustained Virologic Response 56 ug dose 56 CAPACITY trials 56 multicenter phase 56 ONCOLOGY 56 Product Definition 56 MEND CABG 56 SPIRIVA ® 56 Successfully Completes Phase 56 CellPort Technologies 56 Analyte 55 Prevalence Worldwide 55 Ceflatonin R 55 Q4B 55 Late Breaker 55 Neanderthal Genome Project 55 Systemic Delivery 55 Completes Patient Enrollment 55 Optimization Techniques 55 Angiotensin Converting Enzyme 55 Novel Approaches 55 Acute Coronary Syndromes 55 Pemetrexed 55 Interwoven Composite 55 Clinical Guideline 55 Pharmacokinetic parameters 55 CIMZIA ™ 55 ARIS Platform 55 Betaferon R 55 BIO Windhover 55 Dialysis Outcomes 55 Pooled Analysis 55 Oral NKTR 55 multicenter multinational 55 SuperOffice 55 Reveals Significant 55 Rational Software Architect 55 sorafenib tablets 55 Sapacitabine 55 Pharmacogenomic 55 Benign Prostatic Hyperplasia 55 Hematological Cancers 55 PharmaPros 55 radiation dosimetry 55 Randomized Clinical Trials 55 Hypercholesterolemia 55 Pharmacodynamic 55 Cancer Biomarkers 55 EURIDIS 55 ID NCT# 55 Breast Density 55 Asset Lifecycle Management 55 Sidec 55 Nonalcoholic Steatohepatitis 55 p# biomarker 55 PROSTASCINT R 55 Phase IIIb clinical 55 Diabetic Foot Ulcer 55 Currency Majors Technical 55 preclinical efficacy 55 pharmacodynamic parameters 55 Baseline BTM 55 FOREXYARD Daily Forex 55 Histone Deacetylase 55 XPEL Announces 55 Search Engine Reputation 55 Gene Expression Analysis 55 SAS SPSS 55 trastuzumab emtansine T DM1 55 TFT LCD Panels 55 APTIVUS 55 Analytic Applications 55 Immunogenicity 55 Peptidomics 55 MERLIN TIMI 55 Nonclinical 55 human microdosing 55 TestLab 55 Ranolazine 55 Discoverant 55 R#/MEM # 55 RightSourcing 55 multicentre randomized 55 SWX RO SWX ROG 55 CIMZIA TM certolizumab pegol 55 phase IIIb 55 Analytical Methods 55 InForm ™ 55 metastatic neuroendocrine tumors 55 Bionate ® PCU 55 Topics Covered Executive 55 Stent Placement 55 teriflunomide 55 Analytical Method 55 Controlled Trial 55 Preclinical Models 55 Document Output 55 Shows Promise Against 55 EXPLOR 55 CCX# 55 phase IIb 55 ritonavir boosted 55 Exelixis XL# 55 REVEAL Registry 55 #.#/journal.pmed.# 55 Randomized Trials 55 viral kinetics 55 epoetin zeta 55 DNA Methylation 55 Predictive Toxicology 55 lorcaserin Phase 55 YONDELIS 55 randomized controlled Phase 55 EXPLORE Xa 55 uricase 55 placebo controlled Phase III 55 Carfilzomib 55 INNOVATOR 55 Novel Inhibitor 55 Patient Outcomes 55 Novarica ACE Ranking 55 Severe Sepsis 55 Risk Stratification 55 controlled multicenter Phase 55 Safinamide 55 Maven Semantic 55 Membrane Separation Technologies 55 ProviderPoint 55 Interoperability Standards 55 mTOR kinase 54 Randomized Phase II 54 CellCiphr 54 Prognostic Value 54 Randomized Controlled Trials 54 J Am Coll 54 Protein Therapeutics 54 GovWin 54 WinNonlin R 54 HuLuc# 54 SUTENT ® 54 ISCS SurePower Innovation 54 ARCALYST ® rilonacept 54 phase IIa clinical 54 Application Provisioning 54 Medidata Designer 54 Protein Structures 54 J Antimicrob Chemother 54 lexidronam injection 54 Lung Cancer Trial 54 Proc Am Soc 54 Randomized Double Blind 54 xsl template 54 Biosensor System 54 DUROS 54 SAP NetWeaver BI 54 RG# synthetic human 54 ACTEMRA TM 54 CHAMPION PCI 54 DFMA 54 BioElectronics Corporation Announces 54 Adult Stem Cell Therapy 54 Hepatocellular Carcinoma 54 Clinical Trial Results 54 Genta Incorporated OTCBB GETA 54 APTIMA HPV assay 54 Diagnostic Tools 54 Kinase Inhibitor 54 Antifungals 54 Small Molecule 54 KINAXO 54 Biodegradable Polymers 54 Protease Inhibitors 54 Anti Tumor 54 Aplidin R 54 HCV RESPOND 2 54 QUADRAMET R 54 www.aiimexpo.com 54 Sipuleucel T 54 Pink Sheets RHHBY 54 Renal Cancer 54 Phase III Clinical Trials 54 EGIR 54 Virologic 54 Pertuzumab 54 Estybon ™ 54 tipranavir 54 ClearTrial 54 Elagolix 54 Gastric Cancer 54 Autologous Stem Cell Transplantation 54 Meta analyzes 54 Lymphocytic 54 Phase 2b Clinical Trial 54 PubMatic AdPrice Index 54 tolerability pharmacokinetics 54 ALN HPN 54 Phase #/#a 54 brivaracetam 54 Scenario Analysis 54 Outcome Sciences 54 Earned Value 54 ERYtech 54 Application Deployment 54 Satellite Transponders 54 EXECUTIVE SUMMARY 54 Resource Utilization 54 Tyrosine Kinase Inhibitor 54 DecisionSite 54 RG# ITMN 54 RT qPCR 54 Mol Med 54 Tiotropium 54 IRX 54 sunitinib malate 54 -0 Content Outline 54 confirmatory clinical 54 PRESEPT 54 ThermoDox ® clinical 54 Atopic Dermatitis 54 Neoadjuvant Chemotherapy 54 Randomised 54 multicenter prospective 54 ELISA kit 54 Multicenter Randomized 54 microarray gene expression 54 NSABP B 54 JAK Inhibitor 54 elotuzumab 54 Phase III ThermoDox 54 Upcoming Milestones 54 Protein Biomarker 54 Thorough QT 54 VSGi 54 Document Process Automation 54 Mitigate Risk 54 CreekPath Suite 54 Phase Ib clinical 54 Phase #/#a trial 54 Double Blind Randomized 54 Brief Description 54 IMPROVE HF 54 TCGA Pilot Project 54 Recurrent Breast Cancer 54 GLOBOCAN 54 Human Antibody 54 Diabetic Macular Edema 54 ADVANCE PD 54 Intravenous Equipment 54 IT Outsourcing ITO 54 IAOP Global 54 Preclinical Efficacy 54 Albuminuria 54 ILLUMINATE 54 Preclinical Study 54 Pharmacoeconomics 54 RoACTEMRA 54 Receives CCHIT Certification 54 Center Newforma flagship 54 Critical Limb Ischemia CLI 54 CELGENE 54 Product Commercialization 54 HGS# 54 Demonstrates Potential 54 GW# [003] 54 Analytical Tool 54 Decitabine 54 Randomized Study 54 Oral Anticoagulants 54 sipuleucel T 54 UTOPY SpeechMiner 54 Remote Patient Monitoring 54 Fabry Disease 54 Semafore Pharmaceuticals 54 SaaS Showplace 54 Biomarker Study 54 Quantitation 54 Siebel Customer Relationship 54 prospective observational cohort 54 Diagnostic Accuracy 54 Intervention Trial 54 Multiple Ascending Dose 54 Brentuximab Vedotin SGN 54 #:# -# [004] 54 OPM3 54 PremierWest Bancorp Announces 54 Taxonomies 54 DxCG 54 Antibody Therapeutics 54 Therapeutic Monoclonal Antibodies 54 pharmacogenomic translational research 54 BPM Pulse 54 Androxal TM 54 Phase 2b Trial 54 Solumina 54 Screening Trial 54 www.asco.org 54 Brain Metastases 53 Aurora Kinase 53 PEGylated interferon 53 RiskBusiness 53 Management Suite BPMS 53 Orally Active 53 FURTHER DETAILS 53 Recurring Revenue 53 Implementation Methodology 53 Pharma Biotech 53 Neuropsychiatric Inventory NPI 53 Event Correlation 53 SANlogics 53 Specification PAS 53 INTRODUCTION I. 53 Nephrol Dial Transplant 53 Differentiator 53 Modulo Risk Manager 53 phase IIb trial 53 DATATRAK eClinical ™ 53 Degarelix 53 samarium Sm 53 Virtual Histology 53 Respiratory Disorders 53 Topics Covered I. INTRODUCTION 53 Transdermal Patch 53 Halogen eCompensation 53 ADME Tox 53 Backs FY# Forecast 53 www.ilgenetics.com 53 Cegedim Relationship Management 53 Inflammatory Pain 53 Renal Function 53 Novel Therapeutic 53 MAXALT 53 INDUSTRY DEFINITION Industry 53 Operational Efficiency 53 Flow cytometry 53 Clinicaltrials.gov 53 Microbicide 53 Prostate Cancer Outcomes 53 Salary.com SkillsManager 53 randomized multicenter Phase III 53 Sustained Release 53 WinNonlin AutoPilot 53 OneForce 53 INPUT Output 53 Patient Accrual 53 Alexion Soliris 53 EGS# 53 Insight Dashboards 53 VUE Software 53 Oral Insulin 53 azilsartan medoxomil 53 biochemical profiling 53 Database Encryption 53 Suppl. 53 Hyperparathyroidism 53 Home Buyer Seller 53 DataLabs Clinical 53 Oral Mucositis 53 Antiviral Therapy 53 Molecular Diagnostic 53 HDL Mimetic Peptide 53 Broadband Subscriber 53 miRview meso 53 Moxifloxacin 53 Genetic Markers 53 NANOTECH 53 Supply Chain Optimization 53 Glatiramer Acetate 53 IVR IWR 53 Protein Structure 53 Electronic Kanban 53 Chronic HCV 53 LIST OF FIGURES 53 AEG# 53 Combo Therapy 53 Socha Gelbmann survey 53 PMBOK Guide 53 Chronic Obstructive Lung 53 Initiates Clinical Trial 53 GEMS TM 53 xCELLigence System 53 RE LY 53 Pharmacokinetic Study 53 TrialStat 53 Advanced Renal Cell 53 Outsourcing Vendors 53 treatment naive genotype 53 DataLabsXC 53 Virologic Response 53 IMPACT DCM 53 TAXUS ATLAS 53 Kidney Int 53 Golimumab 53 Document Workflow 53 oral laquinimod 53 relapsed MM 53 Tomographic 53 Increased Efficiency 53 mtm laboratories 53 WME ranking 53 RE LY trial 53 neratinib 53 AeroLEF TM 53 mg BID dose 53 BARI 2D 53 Worksoft Certify 53 Eur Urol 53 targeting miR 53 Olmesartan 53 Bucindolol 53 SF #v# 53 Ovarian Cancer Screening 53 IMS MIDAS 53 ExTRACT TIMI 53 Trofex 53 Randomized trials 53 Environ Health Perspect 53 Predict Risk 53 maximally tolerated dose 53 REVIVE Diabetes 53 Omacetaxine 53 Teplizumab 53 Adjuvant Breast Cancer 53 QSAR models 53 aPriori Technologies 53 LAWSON SOFTWARE 53 MAQC 53 Non Alcoholic Steatohepatitis 53 randomized Phase III 53 Ann Rheum Dis 53 PEGylated interferon beta 1a 53 RE SURGE 53 Largest Database 53 DataFlux Data 53 IEX TotalView Workforce 53 Metastatic Melanoma 53 pain palliation 53 MoxDuo ® 53 Biomerk Tumorgrafts 53 WAN Emulation 53 Danske Bank OMX 53 TARGIT 53 TRO# 53 proton MR spectroscopy 53 Hyperwave 53 QTinno 53 Tipranavir 53 Teamcenter Engineering 53 Immunomodulatory 53 Pervasive BI 53 vidofludimus 53 ORBIT Systems 53 basal bolus regimen 53 Parature Customer Service 53 Crystallographic 53 glycoprotein GP IIb IIIa 53 Randomized Clinical Trial 53 WORLDWIDE INC. 53 Solid Tumors 53 Define Measure 53 investigational protease inhibitor 53 Dramatically Improves 53 Enhanced User Experience 53 Hyperion BI 53 Enterprise Data Warehousing 53 ATHANOR 53 iCHECK 53 RE MODEL 53 TUMORS 53 Inc. NASDAQ TIBX 53 IIIa inhibitor 53 www.dendrite.com 53 ORAL Solo 53 SYNTAX 53 Upcoming Webinar 53 Alzheimer Disease Cooperative 53 Xactly Analytics 53 Projected Release Date 53 IEMR Global 53 HORIZONS AMI 53 CDASH 53 Endeca Latitude 53 multivariate statistical 53 Intervention Trial GAIT 53 Carotid Stenting 53 planningIT 53 SVR# 53 ActiveWebflow 53 Parenteral Nutrition 53 rxRNA 53 oral dnaJP1 53 HTRF R 53 OvPlex ™ 53 Practice Guideline 53 Hazardous Drugs 53 Functional Outcomes 53 Hyperlipidemia 53 Tanespimycin 53 Clinical Evaluation 53 Phase #b/#a clinical 53 ST Segment Elevation 53 Confocal Microscopy 53 Capsule Endoscopy 53 eTag assays 53 doi #.# 53 TIBCO BusinessEvents 53 Demonstrated Significant 53 Benchmarking Tool 53 HDAC Inhibitor 53 Vocada Veriphy 53 SOAPSonar 53 Distributive Management 53 CIMZIA TM 53 PlatformOne 53 Heart Failure Therapy 53 somatostatin analog 53 www.smaato.com 52 Phase IIb III 52 Requirements Definition 52 Biopharmaceutical Manufacturing 52 I. INTRODUCTION 52 VALOR trial 52 OVERVIEW OF 52 Percutaneous Tibial Nerve Stimulation 52 M2M Evolution 52 Targeted Therapies 52 Nat Genet 52 Trastuzumab DM1 52 Hepatotoxicity 52 nCounter Analysis System 52 LOCALLY OWNED BY PAMPLIN 52 Intranasal Drug 52 Prospective Randomized Trial 52 Adjuvant Therapy 52 AmberPoint SOA 52 Clostridium difficile Infection 52 Comparative Effectiveness 52 tubulin inhibitor 52 END USE 52 Nasdaq IDRA today 52 Compiere ERP 52 EVALUATE 52 Progress Savvion BPM 52 exploratory endpoints 52 Solar Geophysical Activity 52 antipsychotic efficacy 52 Phase IIa trials 52 Overwatch Geospatial Systems 52 Workflow Solution 52 acute PAO 52 NGFN 52 Companion Diagnostics 52 #PCT 52 Archexin 52 Teva Provides Update 52 Improve Customer Satisfaction 52 Vendor Selection 52 Acute Decompensated Heart Failure 52 PPC Campaigns 52 www.pbmi.com 52 NCCTG N# 52 Clinical Relevance 52 cardio renal 52 Maturity Model Integration 52 Therapeutic Antibodies 52 Sustained virologic response 52 Stent Thrombosis 52 FASEB J. 52 Cimzia TM 52 Chronic Hepatitis C 52 Oracle Agile PLM 52 INEFFECTIVE ASSISTANCE OF COUNSEL 52 Novel Therapies 52 Source Lipper 52 Lead Nurturing 52 ARIS Toolset 52 Phase Ib study 52 Updated DAILY 52 TERANODE 52 Manufacturing Execution 52 REACH Registry 52 Catheter Associated 52 Clin Oncol 52 Pharmacokinetic 52 AurSCOPE 52 www.avatech.com 52 medavis 52 MIVI TRUST 52 Showed Significant 52 Virtual Tape Libraries 52 Beka Publishing 52 Governance Risk Compliance 52 SANmaestro 52 thetreatment 52 demonstrated clinically meaningful 52 Platform ECP 52 Automated Compliance 52 Pandemic Influenza Vaccines 52 TGZ 52 SigmaSure 52 Contrast Enhanced 52 specific CCR9 antagonist 52 Randomized Controlled 52 Competitive Differentiator 52 BPM Workflow 52 PRIALT 52 transcranial Doppler ultrasound 52 CTRC AACR San Antonio 52 Metastatic Renal Cell Carcinoma 52 Bone Metastases 52 TELEPERFORMANCE 52 Ann Oncol 52 Ganite ® 52 Tracleer R 52 synthetic siRNA 52 Zenvia Phase III 52 bepotastine besilate nasal spray 52 Nilotinib 52 Epirubicin 52 Chemotherapeutic Agents 52 Orazol 52 Six Sigma Lean 52 Biological Therapy 52 Investigator Initiated 52 MoxDuo IR 52 Alkeran 52 Confirmit Horizons 52 virological response 52 Kenexa 2x 52 custirsen 52 intravesical infusion therapy 52 WHITE PAPER 52 RECORDATI 52 Dyloject TM 52 Tesmilifene 52 METHODOLOGY 52 Continual Improvement 52 CAMMS# 52 Emerging Markets EM 52 XClinical 52 Calcium Acetate 52 TechRankings 52 PK PD 52 ZyIMAGE IAP 52 Protelos R 52 Audited Financials 52 Aortic Stenosis 52 Diabet Med 52 pharmacodynamic properties 52 Onko Sure TM 52 CINQUIL 52 LIST OF TABLES 52 PhysioLab 52 EmbraceAC 52 Protein Kinase 52 Endpoint Protection Platforms 52 Growth Hormone Deficiency 52 Actelion Pharmaceuticals Ltd 52 Dynamic Logic MarketNorms 52 AIM HIGH 52 Warfarin Coumadin 52 J Immunol 52 MAGE A3 ASCI 52 Pharm Olam International 52 Brain Aneurysms 52 Vitalea 52 CLARITY study 52 European Sepsis Trial 52 Insulin Delivery Systems 52 Segment Highlights 52 Abiraterone Acetate 52 BENCHMRK 52 ROCKET AF 52 chronic myocardial ischemia 52 FOLOTYN ® 52 candidate CRLX# 52 phase IIb study 52 Posaconazole 52 J Allergy Clin 52 DCI Customer Relationship 52 nCircle Suite# 52 ofatumumab HuMax CD# 52 NN# [001] 52 phase Ib 52 Provantis 52 Invasive Fungal Infections 52 DynoChem 52 Closed Loop Marketing 52 Rheumatoid Arthritis Patients 52 ZANTAZ Introspect 52 Continuous Controls 52 Trial PCPT 52 Double Blind Placebo 52 TG MV 52 Analytics Capabilities 52 RenalGuard System TM 52 Sirolimus eluting 52 DataMapper 52 eresource ERP 52 Vildagliptin 52 Anti TNF 52 Liver Fibrosis 52 CA BUSINESS 52 Vendor Relationships 52 Lymphoid 52 Telelogic TAU 52 RELEASE ACCORDING TO 52 Histologic 52 Geochimica et Cosmochimica Acta 52 Feasibility Studies 52 ARCOXIA 52 BENICAR HCT 52 Thromb Haemost 52 Phase 2b monotherapy 52 Elitek 52 SpliceArray 52 Momentum Investing free! 52 EFQM Excellence Model 52 oral deforolimus 52 Estrogen Receptor 52 BENETTON 52 Study Evaluates 52 Solar Photovoltaic Market 52 pharmacokinetic PK study 52 Journyx ProjectXecute 52 Growing Importance 52 Portal Hypertension 52 APEX PD 52 EORTC 52 Integration Capabilities 52 CR# vcMMAE 52 rFSH 52 BIBW 52 Modeling Tool 52 Inflammatory Disease 52 Oral Fluid 52 clevidipine 52 J Rheumatol 52 La Merie 52 Ambrisentan 52 Clinical Practice Guideline 52 PROSTVAC TM 52 Ischemic Stroke 52 initiate multicenter 52 Observational Studies 52 Pivotal Trial 52 Recombinant Human 52 BLOOM Behavioral modification 52 Therapy Evaluation 52 MedNet Solutions 52 Phase III AFFIRM 52 Fibromyalgia Pain 52 Treating Prostate Cancer 52 Scorecarding 52 Non Inferiority 52 Monoclonal Antibodies 52 Refractory Angina 52 LLC QSG 52 Onrigin TM 52 Hiden Analytical 52 prospective multicenter 52 Ibritumomab Tiuxetan 52 Halozyme Ultrafast Insulin 52 HoFH 52 DMAIC 52 GATTEX TM 52 Teraport 52 ONCONASE ranpirnase 52 Pegylated Liposomal Doxorubicin 52 Aethlon Medical Releases 52 Anacetrapib 52 -0 Key 52 Mercury TestDirector 52 XPDL 52 Keynote Transaction Perspective 52 multicenter Phase 52 Search Engine Ranking 52 InRule Technology ® 52 orally inhaled migraine 52 VeriStrat 52 Subgroup Analysis 52 Omnitarg 52 Uterine Fibroid Embolization 52 CNS Disorders 52 Improve Patient Outcomes 52 Patient Oriented 52 Logistic Regression 52 Stent Restenosis 52 Mutational 52 GOUT 52 Deliverables 52 Testing Methodology 52 Renal Cell Carcinoma 52 Bivalirudin 52 oral ridaforolimus 52 MDRNA proprietary 52 ANTEGREN 52 Clinical Significance 52 KIKA Medical 52 Applix TM1 52 goBalto 52 Catheter Ablation 52 SaaS Showplace Award 52 FrontRange HEAT 52 MDL Isentris 52 Frameworx 52 Functioning GAF 52 Chronic Heart Failure 52 Cincom CONTROL 52 TROPOS 52 Anticalin R 52 echocardiographic parameters 52 Hycamtin ® 52 IFN α 52 ARIS PPM 52 gp# vaccine 52 Mammostrat 52 eRA 52 Ampla V#.# 52 Infarct 52 Fecal Incontinence 52 encapsulates siRNAs 52 KALIDO 52 A5 Labs 52 ACR# ACR# 52 PD2i CA Cardiac Analyzer 51 www.standardandpoors.com indices 51 Disease Modification 51 Usability Enhancements 51 ASCO abstract 51 Industrial Enzymes 51 ITO BPO 51 Venous Thromboembolism 51 BioFocus DPI Galapagos 51 ERATO 51 BiTE 51 Performance Metrics 51 Vaxfectin R 51 Novel Compound 51 EQUIP OB 51 Biotracker